RET and medullary thyroid gland carcinoma: In the first 55 consecutively enrolled patients with RET-mutant MTC who had previously received vandetanib, cabozantinib, or both, 69% had a response (95% CI: 55–81) and 1-year PFS was 82% (95% CI: 69–90).